{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:56:05Z","timestamp":1790708165907,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,6]]},"DOI":"10.7759\/cureus.48372","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T16:23:47Z","timestamp":1699287827000},"source":"Crossref","is-referenced-by-count":5,"title":["Multiple Clinical Indications of Mifepristone: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sharon","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S","family":"Ticsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniya","family":"Qadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Rezene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05836-9","article-title":"Medication to manage abortion and miscarriage","volume":"35","author":"Beaman J","year":"2020","unstructured":"Beaman J, Prifti C, Schwarz EB, Sobota M. Medication to manage abortion and miscarriage. J Gen Intern Med. 2020, 35:2398-405. 10.1007\/s11606-020-05836-9","journal-title":"J Gen Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0000000000001063","article-title":"Clinical update on uses for Mifepristone in obstetrics and gynecology","volume":"77","author":"Hagey JM","year":"2022","unstructured":"Hagey JM, Givens M, Bryant AG. Clinical update on uses for Mifepristone in obstetrics and gynecology. Obstet Gynecol Surv. 2022, 77:611-23. 10.1097\/OGX.0000000000001063","journal-title":"Obstet Gynecol Surv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.12.012","article-title":"Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century","volume":"82","author":"Spitz IM","year":"2010","unstructured":"Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010, 82:442-52. 10.1016\/j.contraception.2009.12.012","journal-title":"Contraception"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing's syndrome","volume":"160","author":"Castinetti F","year":"2009","unstructured":"Castinetti F, Fassnacht M, Johanssen S, et al.. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009, 160:1003-10. 10.1530\/EJE-09-0098","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-200110000-00009","article-title":"Rapid reversal of psychotic depression using mifepristone","volume":"21","author":"Belanoff JK","year":"2001","unstructured":"Belanoff JK, Flores BH, Kalezhan M, et al.. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001, 21:516-21.","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02511-5","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger SH","year":"2003","unstructured":"Eisinger SH, Meldrum S, Fiscella K, et al.. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003, 101:243-50. 10.1016\/S0029-7844(02)02511-5","journal-title":"Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300884","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression","volume":"31","author":"Flores BH","year":"2006","unstructured":"Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006, 31:628-36. 10.1038\/sj.npp.1300884","journal-title":"Neuropsychopharmacology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu M","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012, 97:2039-49. 10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein HG","year":"2015","unstructured":"Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr Disord. 2015, 15:63. 10.1186\/s12902-015-0059-5","journal-title":"BMC Endocr Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu M","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab. 2014, 99:3718-27. 10.1210\/jc.2014-1843","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0246","article-title":"Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects","volume":"36","author":"Wallia A","year":"2013","unstructured":"Wallia A, Colleran K, Purnell JQ, Gross C, Molitch ME. Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects. Diabetes Care. 2013, 36:e147-8. 10.2337\/dc13-0246","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12332","article-title":"Global clinical response in Cushing's syndrome patients treated with mifepristone","volume":"80","author":"Katznelson L","year":"2014","unstructured":"Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C. Global clinical response in Cushing's syndrome patients treated with mifepristone. Clin Endocrinol (Oxf). 2014, 80:562-9. 10.1111\/cen.12332","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14866","article-title":"A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis","volume":"24","author":"Che X","year":"2020","unstructured":"Che X, Wang J, He J, et al.. A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020, 24:1724-37. 10.1111\/jcmm.14866","journal-title":"J Cell Mol Med"},{"key":"ref14","article-title":"Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas","volume":"14","author":"Shen Q","year":"2019","unstructured":"Shen Q, Zou S, Sheng B, et al.. Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas. Drug Des Devel Ther. 2019, 14:3161-70.","journal-title":"Drug Des Devel Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.10.015","article-title":"Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study","volume":"101","author":"Yerushalmi GM","year":"2014","unstructured":"Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D, Seidman DS. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril. 2014, 101:496-500. 10.1016\/j.fertnstert.2013.10.015","journal-title":"Fertil Steril"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2161641","article-title":"Clinical evaluation of high-intensity focused ultrasound ablation combined with mifepristone and levonorgestrel-releasing intrauterine system to treat symptomatic adenomyosis","volume":"40","author":"Zhu H","year":"2023","unstructured":"Zhu H, Ma Q, Dong G, Yang L, Li Y, Song S, Mu Y. Clinical evaluation of high-intensity focused ultrasound ablation combined with mifepristone and levonorgestrel-releasing intrauterine system to treat symptomatic adenomyosis. Int J Hyperthermia. 2023, 40:10.1080\/02656736.2022.2161641","journal-title":"Int J Hyperthermia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial","volume":"96","author":"Liu C","year":"2017","unstructured":"Liu C, Lu Q, Qu H, et al.. Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial. Medicine (Baltimore). 2017, 96:e6124. 10.1097\/MD.0000000000006124","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello R","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. Endocr Rev. 2015, 36:385-486. 10.1210\/er.2013-1048","journal-title":"Endocr Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109185","article-title":"Mineralocorticoid receptors dampen glucocorticoid receptor sensitivity to stress via regulation of FKBP5","volume":"35","author":"Hartmann J","year":"2021","unstructured":"Hartmann J, Bajaj T, Klengel C, et al.. Mineralocorticoid receptors dampen glucocorticoid receptor sensitivity to stress via regulation of FKBP5. Cell Rep. 2021, 35:109185. 10.1016\/j.celrep.2021.109185","journal-title":"Cell Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.01.008","article-title":"Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response","volume":"84","author":"Block TS","year":"2018","unstructured":"Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry. 2018, 84:46-54. 10.1016\/j.biopsych.2018.01.008","journal-title":"Biol Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300471","article-title":"Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder","volume":"29","author":"Young AH","year":"2004","unstructured":"Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004, 29:1538-45. 10.1038\/sj.npp.1300471","journal-title":"Neuropsychopharmacology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/191397-multiple-clinical-indications-of-mifepristone-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:04Z","timestamp":1707509344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/191397-multiple-clinical-indications-of-mifepristone-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.48372","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}